Health knowledge made personal
Join this community!
› Share page:
Search posts:


Posted Nov 05 2010 1:39pm
It's FDA-approved (and that's saying something lately).

It's likely the first combination METFORMIN and dipeptidyl peptidase-4 (DPP-4) inhibitor (in this case, ONGLYZA) we'll consider using as it does not include the original formulation of METFORMIN, but instead uses the extended-release ("ER") formulation. The original formulation of METFORMIN is much more likely to promote diarrhea at the doses we'd like to use in most patients.

This combination medication, in Type 2 diabetics, will impact the fasting and postprandial (after eating) blood sugar ... and we don't expect it to lead to weight gain.

One of the press releases is here .

Post a comment
Write a comment:

Related Searches